drugset / Trial / NCT04312594
Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a multi-center, randomized, double-blinded, and placebo-controlled phase II study to evaluate the efficacy and safety of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis.
Timeline
- Start
- 2020-09-08
- Primary completion
- 2022-06-09
- Completion
- 2022-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Jaktinib | Unknown | 50 mg | Oral |
| Subject | Jaktinib | Unknown | 75 mg | Oral |